Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Pulling force deforms hair follicle root sheath nuclei and surrounding dermal collagen matrix differently at infundibulum, isthmus and suprabulbar regions.

Johnson S, Cowley K, Hawkins TJ, Määttä A.

Exp Dermatol. 2019 Jul;28(7):862-866. doi: 10.1111/exd.13948. Epub 2019 May 15.

PMID:
31021445
2.

Reductive Stress Selectively Disrupts Collagen Homeostasis and Modifies Growth Factor-independent Signaling Through the MAPK/Akt Pathway in Human Dermal Fibroblasts.

Carne NA, Bell S, Brown AP, Määttä A, Flagler MJ, Benham AM.

Mol Cell Proteomics. 2019 Jun;18(6):1123-1137. doi: 10.1074/mcp.RA118.001140. Epub 2019 Mar 19.

PMID:
30890563
3.

Role of Internal Lipids in Hair Health.

Marsh JM, Whitaker S, Felts T, Shearouse W, Vatter M, Määttä A, Thompson M, Hawkins TJ.

J Cosmet Sci. 2018 Sep/Oct;69(5):347-356.

PMID:
30767883
4.

Bioengineering the microanatomy of human skin.

Roger M, Fullard N, Costello L, Bradbury S, Markiewicz E, O'Reilly S, Darling N, Ritchie P, Määttä A, Karakesisoglou I, Nelson G, von Zglinicki T, Dicolandrea T, Isfort R, Bascom C, Przyborski S.

J Anat. 2019 Apr;234(4):438-455. doi: 10.1111/joa.12942. Epub 2019 Feb 10.

6.

Publisher Correction: Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice.

Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Määttä A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL.

Nature. 2018 Sep;561(7724):E43. doi: 10.1038/s41586-018-0313-x.

PMID:
30013121
7.

Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice.

Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Määttä A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL.

Nature. 2018 Jun;558(7709):301-306. doi: 10.1038/s41586-018-0198-8. Epub 2018 Jun 6. Erratum in: Nature. 2018 Sep;561(7724):E43.

8.

Recessive Mutation in FAM83G Associated with Palmoplantar Keratoderma and Exuberant Scalp Hair.

Maruthappu T, McGinty LA, Blaydon DC, Fell B, Määttä A, Duit R, Hawkins T, Braun KM, Simpson MA, O'Toole EA, Kelsell DP.

J Invest Dermatol. 2018 Apr;138(4):984-987. doi: 10.1016/j.jid.2017.10.031. Epub 2017 Nov 11. No abstract available.

9.

Vitamin D, high-sensitivity C-reactive protein, and airway hyperresponsiveness in infants with recurrent respiratory symptoms.

Määttä AM, Kotaniemi-Syrjänen A, Malmström K, Malmberg LP, Sundvall J, Pelkonen AS, Mäkelä MJ.

Ann Allergy Asthma Immunol. 2017 Sep;119(3):227-231. doi: 10.1016/j.anai.2017.06.014. Epub 2017 Jul 28.

PMID:
28757230
10.

Maternal Smoking During Pregnancy Is Associated With Offspring's Musculoskeletal Pain in Adolescence: Structural Equation Modeling.

Määttä AJ, Paananen M, Marttila R, Auvinen J, Miettunen J, Karppinen J.

Nicotine Tob Res. 2017 Jul 1;19(7):797-803. doi: 10.1093/ntr/ntw325.

PMID:
28003513
11.

Functional Analysis of Periplakin and Envoplakin, Cytoskeletal Linkers, and Cornified Envelope Precursor Proteins.

Boczonadi V, Määttä A.

Methods Enzymol. 2016;569:309-29. doi: 10.1016/bs.mie.2015.06.019. Epub 2015 Jul 6. Review.

PMID:
26778565
12.

Tomato thymidine kinase-based suicide gene therapy for malignant glioma--an alternative for Herpes Simplex virus-1 thymidine kinase.

Stedt H, Samaranayake H, Kurkipuro J, Wirth G, Christiansen LS, Vuorio T, Määttä AM, Piškur J, Ylä-Herttuala S.

Cancer Gene Ther. 2015 Apr;22(3):130-7. doi: 10.1038/cgt.2014.76. Epub 2015 Jan 23.

PMID:
25613481
13.

Soluble vascular endothelial growth factor receptor-1 improves therapeutic efficacy of suicide gene therapy in an angiogenesis-independent manner.

Samaranayake HD, Pikkarainen JT, Wirth T, Stedt H, Lesch HP, Dragneva G, Vuorio T, Määttä AM, Airenne K, Ylä-Herttuala S.

Hum Gene Ther. 2014 Nov;25(11):942-54. doi: 10.1089/hum.2013.191. Epub 2014 Sep 19.

PMID:
25072110
14.

Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide.

Stedt H, Samaranayake H, Pikkarainen J, Määttä AM, Alasaarela L, Airenne K, Ylä-Herttuala S.

Gene Ther. 2013 Dec;20(12):1165-71. doi: 10.1038/gt.2013.46. Epub 2013 Sep 26.

PMID:
24067866
15.

Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo.

Stedt H, Alasaarela L, Samaranayake H, Pikkarainen J, Määttä AM, Kholová I, Parker AS, Ylä-Herttuala S.

Mol Ther Nucleic Acids. 2012 May 1;1:e19. doi: 10.1038/mtna.2012.13.

16.

Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment.

Leinonen HM, Ruotsalainen AK, Määttä AM, Laitinen HM, Kuosmanen SM, Kansanen E, Pikkarainen JT, Lappalainen JP, Samaranayake H, Lesch HP, Kaikkonen MU, Ylä-Herttuala S, Levonen AL.

Cancer Res. 2012 Dec 1;72(23):6227-35. doi: 10.1158/0008-5472.CAN-12-1166. Epub 2012 Oct 4.

17.

Targeted delivery via avidin fusion protein: intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes.

Soininen SK, Lehtolainen-Dalkilic P, Karppinen T, Puustinen T, Dragneva G, Kaikkonen MU, Jauhiainen M, Allart B, Selwood DL, Wirth T, Lesch HP, Määttä AM, Mönkkönen J, Ylä-Herttuala S, Ruponen M.

Eur J Pharm Sci. 2012 Dec 18;47(5):848-56. doi: 10.1016/j.ejps.2012.09.001. Epub 2012 Sep 14.

PMID:
22985874
18.

Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma.

Lehtinen J, Raki M, Bergström KA, Uutela P, Lehtinen K, Hiltunen A, Pikkarainen J, Liang H, Pitkänen S, Määttä AM, Ketola RA, Yliperttula M, Wirth T, Urtti A.

PLoS One. 2012;7(7):e41410. doi: 10.1371/journal.pone.0041410. Epub 2012 Jul 26.

19.

Annexin A9 is a periplakin interacting partner in membrane-targeted cytoskeletal linker protein complexes.

Boczonadi V, Määttä A.

FEBS Lett. 2012 Sep 21;586(19):3090-6. doi: 10.1016/j.febslet.2012.07.057. Epub 2012 Jul 24.

20.

HRV and EEG based indicators of stress in children with Asperger syndrome in audio-visual stimulus test.

Tiinanen S, Määttä A, Silfverhuth M, Suominen K, Jansson-Verkasalo E, Seppänen T.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:2021-4. doi: 10.1109/IEMBS.2011.6090371.

PMID:
22254732
21.

Plectin regulates invasiveness of SW480 colon carcinoma cells and is targeted to podosome-like adhesions in an isoform-specific manner.

McInroy L, Määttä A.

Exp Cell Res. 2011 Oct 15;317(17):2468-78. doi: 10.1016/j.yexcr.2011.07.013. Epub 2011 Jul 29.

PMID:
21821021
22.

Requirements for baculoviruses for clinical gene therapy applications.

Lesch HP, Makkonen KE, Laitinen A, Määttä AM, Närvänen O, Airenne KJ, Ylä-Herttuala S.

J Invertebr Pathol. 2011 Jul;107 Suppl:S106-12. doi: 10.1016/j.jip.2011.05.010. Review.

PMID:
21784225
23.

A laboratory-scale device for the straightforward production of uniform, small sized cell microcapsules with long-term cell viability.

Kontturi LS, Yliperttula M, Toivanen P, Määttä A, Määttä AM, Urtti A.

J Control Release. 2011 Jun 30;152(3):376-81. doi: 10.1016/j.jconrel.2011.03.005. Epub 2011 Mar 22.

PMID:
21397645
24.

Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery.

Kaikkonen MU, Maatta AI, Ylä-Herttuala S, Airenne KJ.

Mol Ther. 2010 May;18(5):987-92. doi: 10.1038/mt.2010.25. Epub 2010 Feb 23.

25.

Future prospects and challenges of antiangiogenic cancer gene therapy.

Samaranayake H, Määttä AM, Pikkarainen J, Ylä-Herttuala S.

Hum Gene Ther. 2010 Apr;21(4):381-96. doi: 10.1089/hum.2010.017. Review.

PMID:
20163246
26.

Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma.

Määttä AM, Samaranayake H, Pikkarainen J, Wirth T, Ylä-Herttuala S.

Curr Gene Ther. 2009 Oct;9(5):356-67. Review.

PMID:
19860650
27.

Clinical trials for glioblastoma multiforme using adenoviral vectors.

Wirth T, Samaranayake H, Pikkarainen J, Määttä AM, Ylä-Herttuala S.

Curr Opin Mol Ther. 2009 Oct;11(5):485-92. Review.

PMID:
19806496
28.

Dynamic expression of Syndecan-1 during hair follicle morphogenesis.

Richardson GD, Fantauzzo KA, Bazzi H, Määttä A, Jahoda CA.

Gene Expr Patterns. 2009 Sep;9(6):454-60. doi: 10.1016/j.gep.2009.04.004. Epub 2009 May 7.

PMID:
19427408
29.

Avidin fusion protein-expressing lentiviral vector for targeted drug delivery.

Lesch HP, Pikkarainen JT, Kaikkonen MU, Taavitsainen M, Samaranayake H, Lehtolainen-Dalkilic P, Vuorio T, Määttä AM, Wirth T, Airenne KJ, Ylä-Herttuala S.

Hum Gene Ther. 2009 Aug;20(8):871-82. doi: 10.1089/hum.2009.007.

PMID:
19419273
30.

A 96-well format for a high-throughput baculovirus generation, fast titering and recombinant protein production in insect and mammalian cells.

Kärkkäinen HR, Lesch HP, Määttä AI, Toivanen PI, Mähönen AJ, Roschier MM, Airenne KJ, Laitinen OH, Ylä-Herttuala S.

BMC Res Notes. 2009 Apr 23;2:63. doi: 10.1186/1756-0500-2-63.

31.

Epidermal stem cells: location, potential and contribution to cancer.

Ambler CA, Määttä A.

J Pathol. 2009 Jan;217(2):206-16. doi: 10.1002/path.2468. Review.

PMID:
19031472
32.

Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.

Ketola A, Hinkkanen A, Yongabi F, Furu P, Määttä AM, Liimatainen T, Pirinen R, Björn M, Hakkarainen T, Mäkinen K, Wahlfors J, Pellinen R.

Cancer Res. 2008 Oct 15;68(20):8342-50. doi: 10.1158/0008-5472.CAN-08-0251.

33.

The MAGUK-family protein CASK is targeted to nuclei of the basal epidermis and controls keratinocyte proliferation.

Ojeh N, Pekovic V, Jahoda C, Määttä A.

J Cell Sci. 2008 Aug 15;121(Pt 16):2705-17. doi: 10.1242/jcs.025643. Epub 2008 Jul 29.

34.

Replication competent Semliki Forest virus prolongs survival in experimental lung cancer.

Määttä AM, Mäkinen K, Ketola A, Liimatainen T, Yongabi FN, Vähä-Koskela M, Pirinen R, Rautsi O, Pellinen R, Hinkkanen A, Wahlfors J.

Int J Cancer. 2008 Oct 1;123(7):1704-11. doi: 10.1002/ijc.23646.

35.

Characterization of HIV-1 TAT peptide as an enhancer of HSV-TK/GCV cancer gene therapy.

Rautsi O, Lehmusvaara S, Ketola A, Määttä AM, Wahlfors J, Pellinen R.

Cancer Gene Ther. 2008 May;15(5):303-14. doi: 10.1038/cgt.2008.17. Epub 2008 Feb 29.

PMID:
18309353
36.

Mice deficient in involucrin, envoplakin, and periplakin have a defective epidermal barrier.

Sevilla LM, Nachat R, Groot KR, Klement JF, Uitto J, Djian P, Määttä A, Watt FM.

J Cell Biol. 2007 Dec 31;179(7):1599-612. doi: 10.1083/jcb.200706187.

37.

Cytolinker cross-talk: periplakin N-terminus interacts with plectin to regulate keratin organisation and epithelial migration.

Boczonadi V, McInroy L, Määttä A.

Exp Cell Res. 2007 Oct 1;313(16):3579-91. Epub 2007 Jul 14.

PMID:
17662978
38.

Ectopic expression of syndecan-1 in basal epidermis affects keratinocyte proliferation and wound re-epithelialization.

Ojeh N, Hiilesvuo K, Wärri A, Salmivirta M, Henttinen T, Määttä A.

J Invest Dermatol. 2008 Jan;128(1):26-34. Epub 2007 Jul 12.

39.

Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion.

McInroy L, Määttä A.

Biochem Biophys Res Commun. 2007 Aug 17;360(1):109-14. Epub 2007 Jun 15.

PMID:
17585878
40.

Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.

Määttä AM, Liimatainen T, Wahlfors T, Wirth T, Vähä-Koskela M, Jansson L, Valonen P, Häkkinen K, Rautsi O, Pellinen R, Mäkinen K, Hakumäki J, Hinkkanen A, Wahlfors J.

Int J Cancer. 2007 Aug 15;121(4):863-70.

41.

Periplakin-dependent re-organisation of keratin cytoskeleton and loss of collective migration in keratin-8-downregulated epithelial sheets.

Long HA, Boczonadi V, McInroy L, Goldberg M, Määttä A.

J Cell Sci. 2006 Dec 15;119(Pt 24):5147-59.

42.

Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.

Määttä AM, Korja S, Venhoranta H, Hakkarainen T, Pirinen E, Heikkinen S, Pellinen R, Mäkinen K, Wahlfors J.

Int J Mol Med. 2006 Nov;18(5):901-8.

PMID:
17016620
43.

Spectraplakins and nesprins, giant spectrin repeat proteins participating in the organization of the cytoskeleton and the nuclear envelope.

Määttä A, Hutchison CJ, Watson MD.

Symp Soc Exp Biol. 2004;(56):265-77. Review. No abstract available.

PMID:
15565887
44.

Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase/ganciclovir gene therapy.

Ketola A, Määttä AM, Pasanen T, Tulimäki K, Wahlfors J.

Int J Mol Med. 2004 May;13(5):705-10.

PMID:
15067374
45.

Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy.

Määttä AM, Tenhunen A, Pasanen T, Meriläinen O, Pellinen R, Mäkinen K, Alhava E, Wahlfors J.

Int J Oncol. 2004 Apr;24(4):943-9.

PMID:
15010834
46.

Roads to the edge of the cell: Intracellular transport of cornified envelope precursors.

Määttä A.

J Invest Dermatol. 2004 Jan;122(1):xii-xiii. Review. No abstract available.

47.

Gene targeting of envoplakin, a cytoskeletal linker protein and precursor of the epidermal cornified envelope.

Määttä A, DiColandrea T, Groot K, Watt FM.

Mol Cell Biol. 2001 Oct;21(20):7047-53.

48.
49.

Structure and regulation of the envoplakin gene.

Määttä A, Ruhrberg C, Watt FM.

J Biol Chem. 2000 Jun 30;275(26):19857-65.

50.

Supplemental Content

Loading ...
Support Center